(Keynote) Advanced Platform Technologies for the Near Future Electrochemical Biosensing

Abstract

Glucose sensing is the most popular analytical method in the use of the electrochemical biosensing technology. Simultaneously, it is one of the most popular, commercial available, and commoditized biotechnology relating products, where the most advanced but economical materials and technologies are utilized. Current market products in the glucose sensors for the self-monitoring of blood glucose (SMBG) or in the continuous glucose sensing (CGM) systems, the electrochemical principle, either the “1st generation”, which utilizes oxygen as the electron acceptor, or the “2nd generation” principles, which utilizes artificial electron acceptors, has been employed. All other sensing targets by the biochemical analyses in the metabolic disorder syndromes, such as cholesterol, neutral lipid, uric acid, glycated proteins, amino acids, lactates, etc., are also being electrochemically measurable based on these principles, and some are already commercially available. However, recent emergent requirement in the development of accurate and precise sensing systems, which meet the strict regulation with competitiveness in the harsh market of blood glucose monitoring, accelerate the demands in the development of novel platform technologies in the electrochemical biosensing system, which are ready to use in the market grade product. In this presentation, I introduce three indispensable platform technologies which accelerate the development of the near future electrochemical biosensing, especially in the amperometric enzyme sensors; 1) engineered flavin dependent oxidoreductases, 2) disposable interdigitated electrode, and 3) a novel artificial electron acceptor (mediator).